NEW YORK, NY, NEW HAVEN, CT — August 21, 2025 — Leads & Copy — DiamiR Biosciences Corp. has received Clinical Laboratory Evaluation Program Test Approval from the New York State Department of Health for its APOE Genotyping test.
This allows DiamiR to offer its validated APOE Genotyping molecular testing in a variety of biological samples through its Clinical Laboratory Improvement Amendments certified, College of American Pathologists accredited clinical laboratory by licensed healthcare providers in New York State and nationwide.
The APOE test identifies genetic variants associated with risk for late-onset Alzheimer’s disease and other neurological conditions.
On July 14, 2025, DiamiR Biosciences and Aptorum Group Limited entered into a definitive agreement for an all-stock merger transaction. DiamiR Biosciences will become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger.
For DiamiR Biosciences contact Alidad Mireskandari at 203-570-8275 or amireskandari@diamirbio.com.
For Aptorum Group Limited contact Investor Relations Department at investor.relations@aptorumgroup.com or +44 20 80929299.
Source: DiamiR Biosciences
